Summary and Concluding Remarks

Steven George, PT, PhD, FAPTA
Duke University

Liz Turner, PhD
Duke University

Emily O'Brien, PhD
Duke University

Kevin Weinfurt, PhD
Duke University

NIH PRAGMATIC TRIALS COLLABORATORY
Rethinking Clinical Trials®

Wrap-up Thoughts

1

Endpoint location is a choice

- Proximate endpoints may preserve causal signal.
- Distal endpoints may better reflect value to interest holders.
- There is an art to matching endpoint location to the trial's decision purpose.
- There may be value in paradigms that rigorously consider more than one end point

2

Endpoint family matters

- Effectiveness and implementation endpoints choices should be intentional and answer different research questions.
- A null result may be more useful when the endpoint strategy considers how .

3

Hindsight should teach planning

- Retrospective awareness of these endpoint tensions is valuable, but the real value will be expressed when fully exploring these issues in planning phases
- The best discussions explicitly consider assumptions and limitations of endpoint planning
- A reasonable goal is to decrease "endpoint regret" once trial results are known

NIH PRAGMATIC TRIALS COLLABORATORY
Rethinking Clinical Trials®

Join Us for Day 2!

September 9: 11:00 am – 3:00 pm ET

- Moving From Measurement to Meaning
- Unpacking Uncertainty, Meaningfulness, and Magnitude
- Toward Best Practices for Interpretation of Endpoints

Slides and recordings will be posted on rethinkingclinicaltrials.org after the workshop

NIH PRAGMATIC TRIALS COLLABORATORY
Rethinking Clinical Trials®